Can Zenas BioPharma's (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
When biotechnology innovators approach the commercialization cliff, market participants must weigh the clinical promise of a lead asset against the stark realities of surging operating expenses and capital...





